Phase 3Completed

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia (BERSON)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Sponsor
Amgen (Industry)
Enrollment
986 enrolled
Conditions
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab; Atorvastatin; Placebo
Ages
adults, older adults
Registry
NCT02662569, EUCTR2013-000723-14

Full record on ClinicalTrials.gov

From the registry

The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.

Primary outcomes

  • Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
  • Percent Change From Baseline in LDL-C at Week 12

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered